1 October 2015
28 September 2015
Intellectual Property and Access to Medicines
Intellectual Property and Access to Medicines : Affordability is a key determinant of access to medicines. Patents and other intellectual property rules can constitute a major barrier to access by creating market monopolies on
26 June 2015
Launch of Moroccan Generic Sofosbuvir: A Victory for the Wide-spread Use HCV Treatmen…
According to the Ministry of Health, 625,000 people are infected by HCV, 1.6% of the general population of Morocco. Of those infected, 267,000 people have active chronic infection requiring treatment. Until recently, the management
20 May 2015
Treatment Advocates Denounce Gilead’s Embargo against Thousands of Tunisians Sufferin…
The Tunisian Association of Fight against STDs and AIDS (ATL Tunis) and the International Treatment Preparedness Coalition in MENA Region (ITPC-MENA) denounce the refusal of Gilead Sciences to make their drug against the Hepatitis
10 July 2014
The first Middle East and North Africa Community Advisory Board (MENA-CAB)
Casablanca, Morocco, 28 June-01 July 2014 Despite the fact that HIV prevalence in the countries of the Middle East and North Africa is believed to be low at least among the General Population, the
28 February 2014
Pharma Refuses to Ensure Access to Lifesaving Hepatitis C Treatment at Global Meeting
Bangkok, Thailand, February 28, 2014 —Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus
30 November 2013